# Safety and Dose-finding Study of DC-TAB in Healthy Subjects

> **NCT02442557** · PHASE1 · COMPLETED · sponsor: **Delta Crystallon BV** · enrollment: 76 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** recombinant human alpha B-crystallin
- **OTHER:** placebo comparator

## Key facts

- **NCT ID:** NCT02442557
- **Lead sponsor:** Delta Crystallon BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2010-10
- **Final completion:** 2011-07
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2015-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02442557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02442557, "Safety and Dose-finding Study of DC-TAB in Healthy Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02442557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*